Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.51 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850160 | 1.00 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778544 | 1.00 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2119635 | 1.00 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778546 | 1.00 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL29391128 | 0.97 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL1053800 | 0.97 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL4960887 | 0.97 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL28204655 | 0.97 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6026166 | 0.97 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL3462001 | 0.97 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506628-B1 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA TAU IND FARMACEUTI (IT) | 1996-09-18 | — | — | EP | claimed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | claimed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | claimed |
| CN-114295821-B | Laboratory interstitial evaluation sample of thrombus elastography experiment reagent, and preparation method and application thereof | 深圳麦科田生物医疗技术股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-6903107-B1 | Serine protease inhibitor | AKZO NOBEL N.V. (NL) | 2005-06-07 | — | — | US | disclosed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1123280-A1 | SERINE PROTEASE INHIBITOR | Akzo Nobel N.V. (NL) | 2001-08-16 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| US-5298621-A | Peptides endcapped with purine derivative | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5298621-A | Peptides endcapped with purine derivative | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5272151-A | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-21 | — | — | US | disclosed |
| US-5272151-A | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-21 | — | — | US | disclosed |
| EP-0506628-A3 | AMINOACYL AND OLIGOPEPTIDYL DERIVATIVES OF ALLOPURINOL EXHIBITING IMMUNOSTIMULATORY ACTIVITY, AND PHARMACEUTICAL FORMULATIONS CONTAINING THESE SUBSTANCES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-10-21 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | F2 1627/4885OPRM1 3038/4885OPRD1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.